DekaBank Deutsche Girozentrale decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 3.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 227,500 shares of the company’s stock after selling 8,083 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.06% of Moderna worth $26,866,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Cubist Systematic Strategies LLC boosted its stake in shares of Moderna by 465.9% in the third quarter. Cubist Systematic Strategies LLC now owns 41,489 shares of the company’s stock valued at $2,935,000 after buying an additional 34,158 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in shares of Moderna by 8.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 158,691 shares of the company’s stock valued at $16,582,000 after buying an additional 12,842 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of Moderna in the fourth quarter valued at approximately $1,807,000. Stonebridge Financial Planning Group LLC boosted its stake in shares of Moderna by 12.0% in the fourth quarter. Stonebridge Financial Planning Group LLC now owns 1,865 shares of the company’s stock valued at $195,000 after buying an additional 200 shares during the period. Finally, ProShare Advisors LLC boosted its stake in shares of Moderna by 14.8% in the fourth quarter. ProShare Advisors LLC now owns 395,137 shares of the company’s stock valued at $41,280,000 after buying an additional 50,961 shares during the period. Institutional investors and hedge funds own 51.21% of the company’s stock.
NASDAQ MRNA opened at $131.47 on Thursday. The company has a market capitalization of $52.66 billion, a price-to-earnings ratio of -81.15, a PEG ratio of 0.53 and a beta of 1.73. Moderna, Inc. has a twelve month low of $31.32 and a twelve month high of $189.26. The stock has a fifty day simple moving average of $142.99 and a 200 day simple moving average of $120.18. The company has a quick ratio of 2.43, a current ratio of 2.43 and a debt-to-equity ratio of 0.04.
In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Wednesday, January 13th. The stock was sold at an average price of $123.70, for a total transaction of $1,855,500.00. Following the completion of the sale, the president now directly owns 1,644,597 shares in the company, valued at approximately $203,436,648.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Noubar Afeyan sold 1,836,766 shares of the stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $164.22, for a total value of $301,633,712.52. Following the sale, the director now owns 2,101,703 shares of the company’s stock, valued at $345,141,666.66. The disclosure for this sale can be found here. Insiders sold 5,667,766 shares of company stock valued at $824,359,096 over the last 90 days. 29.20% of the stock is currently owned by company insiders.
Several equities research analysts recently issued reports on the company. Bank of America reiterated a “sell” rating and issued a $140.00 price target on shares of Moderna in a research note on Friday, February 26th. The Goldman Sachs Group restated a “buy” rating and set a $139.00 target price on shares of Moderna in a research note on Friday, December 11th. Jefferies Financial Group upped their target price on Moderna from $150.00 to $180.00 in a research note on Thursday, February 18th. Chardan Capital upped their target price on Moderna from $107.00 to $182.00 and gave the stock a “buy” rating in a research note on Monday, March 8th. Finally, Brookline Capital Management upped their target price on Moderna from $180.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, March 4th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $150.56.
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
Recommended Story: What is the 52-week high/low?
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.